Valuation: Design Therapeutics, Inc.

Market Cap 597M 544M 503M 455M 854M 55.74B 894M 6.08B 2.41B 30.12B 2.24B 2.19B 95.41B P/E 2026 *
-7x
P/E 2027 * -5.84x
Enterprise Value 405M 369M 342M 309M 580M 37.85B 607M 4.13B 1.64B 20.45B 1.52B 1.49B 64.79B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-1.39%
1 week-12.42%
Current month-14.14%
1 month-17.39%
3 months-41.07%
6 months-17.39%
Current year-2.24%
1 week 9.17
Extreme 9.17
10.46
1 month 9.17
Extreme 9.17
11.42
Current year 8.23
Extreme 8.23
17.25
1 year 7.82
Extreme 7.8201
17.25
3 years 2.13
Extreme 2.13
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 24/08/2023
Chief Tech/Sci/R&D Officer 60 16/04/2025
Chief Tech/Sci/R&D Officer - 31/01/2025
Director TitleAgeSince
Chairman 56 17/12/2017
Director/Board Member 71 30/06/2019
Director/Board Member 49 31/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
31/03/26 Free

Director

67,500 0.1185%
02/01/26 Free

Chief Executive Officer

750,000 1.3166%
02/01/26 Free

Director

45,000 0.0790%
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%-12.42%+16.52%+311.21% 597M
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-2.91%+6.20%+89.22% 58.91B
-2.37%-2.22%+22.87%+82.31% 55.24B
-1.07%-4.87%+13.45%+110.91% 45.66B
-0.66%-6.12%+14.64%+21.24% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.77%-5.56%+132.85%+648.80% 34.48B
-0.80%+0.61%+77.26%+56.26% 32.5B
+0.52%+19.90%-27.23%+490.05% 31.69B
Average -0.77%-1.78%+32.84%+192.00% 40B
Weighted average by Cap. -0.93%-1.29%+32.77%+152.92%

Financials

2026 *2027 *
Net sales - -
Net income -83.32M -75.91M -70.27M -63.56M -119M -7.78B -125M -849M -337M -4.2B -313M -306M -13.32B -113M -103M -95.71M -86.57M -162M -10.6B -170M -1.16B -459M -5.73B -426M -417M -18.14B
Net Debt -192M -175M -162M -146M -274M -17.89B -287M -1.95B -775M -9.67B -719M -704M -30.62B -182M -166M -154M -139M -261M -17.03B -273M -1.86B -737M -9.2B -684M -670M -29.15B
Projected Income Statement - Annual - Design Therapeutics, Inc.
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
60
Date Price Change Volume
20/11/26 US$9.170 -1.61% 62,151
19/11/26 US$9.320 -1.58% 266,861
18/11/26 US$9.470 -3.76% 319,965
17/11/26 US$9.840 -0.81% 294,391
16/11/26 US$9.920 -5.25% 301,609
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Design Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.320USD
Average target price
21.57USD
Spread / Average Target
+131.45%
  1. Stock Market
  2. Stocks
  3. DSGN Stock